TGTX Stock Cash Flow Statements

TG Therapeutics Quarterly Cash Flow Statements Chart

Quarterly

Annual

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

TG Therapeutics Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2011-09-30	2011-06-30	2011-03-31	2010-06-30	2008-03-31

cash flows from operating activities

net income	28,187,000	5,060,000	23,331,000	3,880,000	6,879,000	-10,707,000	-14,416,000	113,929,000	-47,609,000	-39,232,000	-52,994,000	-35,818,000	-40,510,000	-69,013,000	-93,338,000	-85,638,000	-78,497,000	-90,628,000	-88,218,000	-87,163,000						-35,156,000		-33,951,000	-44,142,000	-41,529,000		-31,535,652	-28,353,084	-27,727,509		-24,831,027	-15,899,062	-13,848,662											-1,559,474
adjustments to reconcile net income to net cash from operating activities:
noncash stock compensation expense	16,361,000	14,972,000	11,948,000	11,773,000	9,481,000	9,339,000	9,385,000	9,184,000	12,541,000	6,823,000	11,051,000	6,988,000	-975,000	2,121,000	14,356,000	13,996,000	16,304,000	16,618,000	33,521,000	28,330,000				2,075,000	1,757,000	1,882,000	1,458,000	-173,000	4,264,000	7,337,000	3,569,978	4,890,123	1,489,728	5,995,455	1,328,599	2,834,038	1,648,397	1,698,965	2,857,044	1,240,034	6,242,986	5,357,028	5,038,436	4,096,572
depreciation and amortization	13,000	8,000	9,000	11,000	19,000	29,000	38,000	73,000	32,000	68,000	73,000	76,000	78,000	76,000	80,000	76,000	67,000	59,000	53,000	41,000	34,000	30,000
amortization of premium (discount) on investment securities	-1,283,000	-1,336,000		-1,817,000	-1,800,000	-1,670,000	-1,532,000	-217,000	-186,000	-301,000	-159,000
amortization of debt issuance costs	304,000	304,000	303,000	414,000	639,000	639,000	639,000																	231,000	231,000	77,000
amortization of leasehold interest	46,000	48,000	53,000	53,000	53,000	53,000	53,000
noncash change in lease liability and right of use asset	432,000	453,000	498,000	497,000	498,000	407,000	490,000
change in fair value of equity investments	181,000	104,000	501,000	75,000	373,000	-195,000
change in fair value of notes payable	-64,000	213,000	153,000	127,000	59,000	-35,000	184,000	-332,000	202,000	59,000	125,000	35,000	-98,000	-178,000	-263,000	-94,000	-163,000	-58,000	462,000	134,000	172,000	-20,000						-119,000				29,588					-31,752	-58,632	36,805	-113,692	23,154	-2,984	92,046	23,930
changes in assets and liabilities:
increase in inventory	3,595,000	-46,305,000	-24,820,000	-2,540,000	-2,560,000	-36,931,000
increase in other current assets	-5,260,000	-4,627,000	16,731,000																			-1,057,000					1,783,000	-2,208,000									-3,449,803	-2,250,490	949,345	1,061,924	-957,985	-4,159,055	3,022,889	-5,201,987
increase in accounts receivable	-41,395,000	-60,936,000	-13,458,000	-32,119,000	-18,626,000	-13,889,000
increase in accounts payable and accrued expenses	5,565,000	65,585,000	-38,012,000	11,669,000	8,959,000	40,222,000			9,278,000	9,858,000	16,426,000	-6,081,000	-11,185,000	-10,170,000	3,901,000	8,819,000	2,367,000	904,000	5,738,000			-1,567,000	-958,000			2,240,000	-1,364,000	3,423,000	3,606,000	5,292,000	8,353,870	-401,751	516,189	2,551,726	45,429	2,735,203	5,287,986	-1,575,974	812,787	639,361	-416,046	4,434,813	-3,873,006	6,271,742
decrease in lease liabilities	-518,000	-543,000	-598,000	-597,000	-597,000	-596,000	-595,000
increase in other current liabilities	-515,000	-1,855,000	1,178,000	-795,000	611,000	3,035,000	651,000	701,000	704,000	619,000	874,000	-337,000	1,201,000	539,000										22,263,000
increase in deferred revenue	1,787,000	140,000	-1,761,000	18,144,000	498,000	602,000	-926,000
net cash from operating activities	7,436,000	-28,715,000	-25,641,000	-12,205,000	5,536,000	-8,207,000	-13,210,000	83,704,000	-42,005,000	-59,902,000	-23,870,000	-34,495,000	-49,116,000	-68,689,000	-86,909,000	-67,201,000	-60,169,000	-81,355,000	-52,026,000	-56,532,000	-43,834,000	-62,115,000	-30,393,000			-33,351,000	-33,690,000	-33,009,000	-34,183,000	-28,043,000	-21,855,129	-22,776,473	-26,829,596	-22,302,364	-17,025,067	-15,042,201	-12,850,521	-16,673,541	-12,900,661	-10,658,732	-12,248,526	-8,882,353	-15,106,938	-8,050,975				445,987	-1,461,625
capex	-42,000	-25,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-175,000	-67,000	-155,000	-89,000	-45,000	-68,000	-34,000			-14,000	0	0	-34,000	-24,000	0	0	0	0	-20,970	0	-27,795	-282,261	16,977	0	-13,397	-6,883	-14,072	-1,333				0	0
free cash flows	7,394,000	-28,740,000	-25,641,000	-12,205,000	5,536,000	-8,207,000	-13,210,000	83,704,000	-42,005,000	-59,902,000	-23,870,000	-34,495,000	-49,116,000	-68,689,000	-86,909,000	-67,201,000	-60,344,000	-81,422,000	-52,181,000	-56,621,000	-43,879,000	-62,183,000	-30,427,000			-33,365,000	-33,690,000	-33,009,000	-34,217,000	-28,067,000	-21,855,129	-22,776,473	-26,829,596	-22,302,364	-17,046,037	-15,042,201	-12,878,316	-16,955,802	-12,883,684	-10,658,732	-12,261,923	-8,889,236	-15,121,010	-8,052,308				445,987	-1,461,625
cash flows from investing activities
proceeds from maturity of held-to-maturity securities
investment in held-to-maturity securities	-53,300,000	-92,059,000	-57,891,000	-101,360,000	-69,734,000	-81,531,000	-68,433,000	-56,279,000	0	-22,168,000	-3,998,000	-31,466,000	-14,921,000	-56,889,000	-12,232,000	-11,802,000	-14,050,000	-17,447,000	-59,921,000	0	0	-7,482,000				-8,171,000	-6,656,000	-17,609,000	-2,781,000	-4,184,000					0	0	-4,558,652	-10,641,270	-8,038,515
investment in equity investments
purchases of property, plant and equipment	-42,000	-25,000																														0					-27,795	-282,261	16,977
net cash from investing activities	-3,992,000	-12,934,000	15,788,000	-9,334,000	1,765,000	-9,255,000	-44,755,000	-30,229,000	30,501,000	-6,168,000	16,269,000	-2,990,000	10,379,000	-43,671,000	3,288,000	-631,000	-2,475,000	-514,000	-52,076,000	14,911,000	11,205,000	1,450,000	4,000			-1,135,000	238,000	-6,435,000	5,585,000	1,792,000	-28,006,270	8,800,000	4,997,773	6,000,000	11,479,030	15,576,260	1,413,553	-1,923,531	2,478,462	76,574	-31,084,022	3,843,117	-9,132,783	-1,333				530,141	-13,620
cash flows from financing activities
proceeds from exercise of options	432,000	21,000	570,000	199,000	135,000	10,000	0															81,000
purchase of treasury stock	-6,875,000	-6,123,000	-6,611,000
net cash from financing activities	-6,443,000	-6,102,000	-6,072,000	134,454,000	135,000	10,000	-1,000	421,000	47,047,000	25,238,000	49,000	275,000	135,000	-850,000	55,997,000	-7,361,000	-7,162,000	-55,000	403,389,000	35,265,000	241,092,000	81,000	98,354,000	20,695,000	28,284,000	56,880,000	4,694,000	4,492,000	52,023,000	52,430,000	14,737,079	28,216,277	3,796,614	86,908,656	1,420,796	44,630	3,536,380	14,163	21,588	15,744,012	17,628,189	35,329,897	26,727,706	24,200,130				94,469	1,958,683
net decrease in cash, cash equivalents and restricted cash	-2,999,000	-47,751,000			7,436,000	-17,452,000						-37,210,000	-38,602,000	-113,210,000				-81,924,000
cash, cash equivalents and restricted cash at beginning of period	0	181,192,000	0	0	0	94,218,000	0	0	0	103,577,000	0	0	0	300,151,000	0	0	0	554,698,000		0	1,000	113,887,000		0	0	43,199,000		0	0	57,305,000
cash, cash equivalents and restricted cash at end of period	-2,999,000	133,441,000	-15,925,000	112,915,000	7,436,000	76,766,000	-57,966,000	53,896,000	35,543,000	62,745,000	-7,552,000	-37,210,000	-38,602,000	186,941,000	-27,624,000	-75,193,000	-69,806,000	472,774,000		-6,356,000	208,464,000	53,303,000		-12,551,000	-7,119,000	65,593,000		-34,952,000	23,425,000	83,484,000
reconciliation to amounts on condensed consolidated balance sheets:
cash and cash equivalents	-3,013,000	132,139,000	-15,928,000	112,912,000	7,433,000	75,477,000	-57,969,000	53,893,000	35,540,000	61,469,000	-7,556,000	-37,213,000	-38,603,000	185,676,000	-27,625,000	-75,195,000	-69,807,000	471,514,000	299,285,000	-6,358,000	208,461,000	52,051,000	67,962,000	-12,553,000	-7,121,000	64,349,000	-28,760,000	-34,954,000	22,776,000	82,896,000
restricted cash	14,000	1,302,000	3,000	3,000	3,000	1,289,000	3,000	3,000	3,000	1,276,000	4,000	3,000	1,000	1,265,000	1,000	2,000	1,000	1,260,000	2,000	2,000	3,000	1,252,000	3,000	2,000	2,000	1,244,000	2,000	2,000	649,000	588,000
total cash, cash equivalents and restricted cash	-2,999,000	133,441,000	-15,925,000	112,915,000	7,436,000	76,766,000	-57,966,000	53,896,000	35,543,000	62,745,000	-7,552,000	-37,210,000	-38,602,000	186,941,000	-27,624,000	-75,193,000	-69,806,000	472,774,000	299,287,000	-6,356,000	208,464,000	53,303,000	67,965,000	-12,551,000	-7,119,000	65,593,000	-28,758,000	-34,952,000	23,425,000	83,484,000
cash paid for:
interest	6,097,000	6,143,000	6,422,000	7,112,000	2,488,000	2,448,000	2,433,000	2,409,000	2,180,000	1,749,000	1,537,000	1,286,000	1,038,000	1,584,000	768,000	604,000	1,325,000	769,000	1,054,000	1,892,000	778,000	777,000
income taxes
proceeds from maturity of short-term securities		80,400,000	73,700,000	92,300,000	71,499,000	73,401,000	23,678,000	26,050,000	30,501,000	16,000,000	20,270,000	28,480,000	25,300,000	13,225,000	15,600,000	11,250,000	11,750,000	17,000,000	8,000,000	15,000,000	11,250,000	9,000,000	6,750,000	9,000,000	6,450,000	7,050,000	6,900,000	11,200,000	8,400,000	6,000,000	0	8,800,000	5,000,000	6,000,000	11,500,000	3,000,000	6,000,000	9,000,000	10,500,000	6,000,000	4,000,000	3,850,000
investment in long-term securities		-1,250,000	0	-250,000	0	-1,125,000
loss on extinguishment of debt			0
amortization of discount on investment securities
purchases of ppe											-3,000	-4,000	0	-7,000	-80,000
payment of loan payable			0
proceeds from sale of common stock																							98,357,000	20,699,000	28,287,000	27,678,000	4,694,000	4,492,000	52,023,000	52,430,000	14,737,079	28,216,275	3,796,615	84,765,572	906,972	0			0	15,775,638	17,043,830	34,941,049	26,056,167	22,766,685
proceeds from debt financings			0				0																	-4,000	-61,000	29,740,000
financing costs paid			-31,000				0	0	0	-125,000													-315,000			-538,000
net increase in cash, cash equivalents and restricted cash			-15,925,000							-40,832,000					-27,624,000	-75,193,000			299,287,000	-6,356,000	208,463,000	-60,584,000	67,965,000	-12,551,000	-7,119,000	22,394,000	-28,758,000	-34,952,000	23,425,000	26,179,000
reconciliation to amounts on consolidated balance sheets:
noncash transactions
deferred financing costs							0	0															0	0	-169,000	1,157,000
warrants issued with debt financing							0	0															0	0	0	993,000
issuance of common stock
decrease (increase) in other current assets					1,050,000	1,490,000
decrease (increase) in accounts receivable
decrease in accounts payable and accrued expenses																																													-39,930	24,369	-40,236
decrease in deferred revenue									-38,000	-38,000	-38,000	-38,000	-38,000	-38,000	-38,000	-38,000	-38,000	-38,000	-38,000	-38,000	-38,000	-38,000	-38,000			-38,000	-38,000	-38,000	-38,000	-38,000	-38,095	-38,095	-38,096	-38,095	-38,095	-38,095	-38,095	-38,096	-38,095	-38,095	-38,096	-38,095	-38,095	-38,095
offering costs paid																-21,000	0	-183,000
amortization of premium on investment securities													-40,000	23,000	96,000	139,000	155,000	127,000	45,000	-6,000	-25,000	-44,000	-48,000			-75,000	-68,000	-42,000	-11,000	2,000	7,460	8,930	14,402	30,528	91,756	113,541	125,803	128,329	158,372	172,361	124,812	80,597	66,321	60,317
shares issued in connection with in-licensing agreement
shares issued in connection with in-licensing																							0
decrease in other current liabilities																										-559,000
decrease in other liabilities																	-146,000	-3,717,000				-18,898,000
purchases of equipment																	-175,000	-67,000	-155,000	-89,000	-45,000	-68,000	-34,000			-14,000			-34,000	-24,000					-20,970						-13,397	-6,883	-14,072	-1,333
increase in accrued interest receivable																																							-27,494	31,786	-100,603	-4,194	-31,695	20,861
increase in lease liabilities
increase in interest payable																								344,000	-106,000	549,000																	0	0	277,328	285,724	280,509
increase in other liabilities																			-3,679,000	-4,319,000
cash, cash equivalents and restricted cash at beginning of year
cash, cash equivalents and restricted cash at end of year
noncash licensing expense																								0				0
noncash change in lease liability and right-of-use asset
decrease in other current assets
decrease in accrued interest receivable																						40,000				14,000		6,000	-8,000	30,000				61,028
investment in short-term securities
decrease in leasehold interest																									45,000	46,000		45,000	20,000	33,000
decrease (increase) in accrued interest receivable																																			24,606	25,308	30,340	21,915
accrued offering costs																									-119,000	179,000								190,709
consolidated net income																						-51,116,000																	-17,611,812	-13,655,916	-17,103,183	-14,577,735		-17,451,169
non-cash stock compensation expense																						11,068,000
non-cash change in lease liability and right-of-use asset																									529,000	373,000
adjustments to reconcile consolidated net income to net cash from operating activities:
change in fair value of notes payable and accrued interest																							96,000	-50,000	12,000	66,000				96,000				105,782	-45,835
decrease in other assets																																		242,372				5,341				25,913
increase in deferred rent																											26,000	25,000	23,000	23,000	31,401	28,364	22,289	22,289	22,289	112,248
proceeds from the exercise of warrants																															0	2	-1	2,143,084	517,346	50,625	28,108	22,163	57,354	17,341	584,358	408,286	666,319	1,288,245
reclassification of deferred financing costs to additional paid-in capital																																							-48,022	-15,017
cash flows from operating activities:
depreciation																								26,000	23,000	23,000		23,000	21,000	20,000		20,939	20,654	20,416	20,496	19,145	16,939	6,380	5,126	4,521	3,386	2,419	1,477	896	236	411	757	-5,529	7,912
decrease (increase) in prepaid research and development and other current assets																								1,563,000						691,000
decrease in lease liability																										-339,000
cash flows from investing activities:
cash flows from financing activities:
noncash transactions:
shares to be issued in connection with in-licensing
increase in prepaid research and development and other current assets																										-2,454,000								-3,584,938
gain on sale of long-term securities																																			0
decrease (increase) in leasehold interest																															36,768	13,147	55,445	19,587
decrease (increase) in other assets																															0
proceeds from the sale of long-term securities																																			0
deferred financing costs paid																																									1	-19,438
reclassification of deferred financing costs to additional paid-in capital																															0	0	0	-2,645	31,891	0
conversion of convertible notes payable to common stock																																			2,416	0
accrued financing cost
increase in restricted cash																															-1,032	-1,030	-1,016	-1,005	-1,024	-1,023	-1,010	-1,008	-1,017	-1,016	-1,038	-1,060
net increase in cash and cash equivalents																															-35,124,320	14,239,804	-18,035,209	70,606,292	-4,125,241	578,689	-7,900,588	-18,582,909	-10,400,611	5,161,854	-25,704,359	30,290,661	2,487,985		-280,228	-98,808	112,648	1,070,597	483,438
cash and cash equivalents at beginning of year
cash and cash equivalents at end of year
financing costs																																				-5,995	4,011	-8,000
cash and cash equivalents at beginning of period																																0	0	25,031,280		0	0	55,061,329		0	0	55,713,784		0	0	0	478,668	-631,690	649,686
cash and cash equivalents at end of period																																14,239,804	-18,035,209	95,637,572		578,689	-7,900,588	36,478,420		5,161,854	-25,704,359	86,004,445		16,147,822	-280,228	-98,808	591,316	438,907	1,133,124
increase in other assets																																			-1,261	5,995
accrued financing costs
gain on settlement of notes payable																																												0
noncash stock expense associated with in-licensing agreements																																											0
increase in leasehold interest																																			475,490	-549,037
decrease in interest payable
proceeds from the exercise of options																																											57,200
payment of notes payable																																											0	0
deferred rent																																						389,554
increase in prepaid rent																																						-1,151,163
impairment of in-process research and development
noncash stock expense associated with in-licensing agreement
investment in held-to-maturity long-term securities
investment in held-to-maturity short-term securities																																											-9,118,711	-6,127,539
changes in assets and liabilities, net of effects of acquisition:
gain on settlement of note payable
net decrease in cash and cash equivalents
stock compensation expense
cash acquired in connection with acquisition
payments of short-term loans
proceeds from sale of preferred stock
conversion of notes payable to preferred stock
net income/																																													-551,739	-2,982,539	3,832,383
adjustments to reconcile net income/(loss) to net cash from operating activities:
equity in losses of hedrin jv
non cash gain on nordic settlement																																													0	0	-4,017,488
share-based compensation																																													5,597	5,536	8,077	13,287	192,854
amortization of oid, issue costs and beneficial conversion feature																																													887,198
change in fair value of derivative liability																																													-2,100,898	2,231,746	-170,435
loss on early extinguishment of debt
shares issued in connection with ariston milestone																																													0	0	220,701
warrants issued to consultant
amortization of intangible assets
gain on sale of marketable equity securities
noncash portion of in-process research and development charge
loss on impairment and disposition of intangible assets
other
changes in operating assets and liabilities, net of acquisitions:
decrease in grant receivable																																													0
decrease in prepaid expenses and other current assets																																													16,068
decrease/(increase) in other assets																																													0	0	10,859
purchase of property and equipment
cash acquired in connection with acquisitions
net cash provided from the purchase and sale of short-term investments
proceeds from sale of license
proceeds related to sale of common stock
proceeds from the hedrin jv agreement
proceeds from sale of notes payable
sale of warrant
net repayments of notes payable																																													0	0	-100,000
net cash provided by/(used in) financing activities																																													0	0	-100,000
adjustments to reconcile net income/(loss) to net cash provided by/(used in) operating activities:
net cash provided by/(used in) operating activities																																														-98,808	212,648
amortization of oid and issue costs																																															12,062
increase in grant receivable
increase in prepaid expenses and other current assets																																															75,459
amortization of oid and issue costs on secured 12% notes
decrease in restricted cash
decrease/(increase) in prepaid expenses and other current assets
increase/(decrease) in accounts payable and accrued expenses
increase in interest payable, current portion
increase in interest payable, noncurrent portion
repayments of notes payable
proceeds from exercise of warrants and stock options and sale of warrant
interest and amortization of oid and issue costs
change in fair value of derivative
non-cash portion of in-process research and development charge
decrease (increase) in prepaid expenses and other current assets
proceeds from sale of secured 12% notes
proceeds from sale of convertible 12% notes
proceeds from 8% note
repayment of 8% note
proceeds from (repayments of) notes payable
repayment of secured 10% notes
non cash portion of in-process research and development charge
(increase)/decrease in prepaid expenses																																																	-17,693
increase /(decrease) in accounts payable																																																	-293,262
increase in accrued expenses																																																	208,038
cash paid in connection with acquisitions
proceeds from the sale of license
investment in hedrin jv’s general partner																																																	-13,620
repayments of notes payable to stockholders
proceeds from exercise of warrants and stock options
proceeds from the put and warrant issued in the hedrin jv																																																	1,958,683
supplemental disclosure of cash flow information:
interest paid
supplemental disclosure of noncash investing and financing activities:
common stock issued in satisfaction of accounts payable
imputed preferred stock dividend
preferred stock dividends accrued
preferred stock dividends paid by issuance of shares
conversion of preferred stock to common stock
issuance of common stock for acquisitions
issuance of common stock in connection with in-licensing agreement
marketable equity securities received in connection with sale of license
net liabilities assumed over assets acquired in business combination
cashless exercise of warrants

We provide you with 20 years of cash flow statements for TG Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of TG Therapeutics stock. Explore the full financial landscape of TG Therapeutics stock with our expertly curated income statements.

The information provided in this report about TG Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.